63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)

Vertex at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)

Vertex will present data on INCIVEK® (telaprevir) tablets, approved for the treatment of genotype 1 hepatitis C in adults with compensated liver disease, and two of its hepatitis C medicines in development, the uridine nucleotide analog pro-drug ALS-2200 (VX-135) and the non-nucleoside polymerase inhibitor VX-222 at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston, November 9 to 13, 2012.

The titles of the 11 accepted abstracts are included below. The complete abstracts are now available through the AASLD website at www.aasld.org.

Media Contacts 617-444-6992
Dawn Kalmar
Erin Emlock
Zachry Barber

Investor Relations Contacts
Michael Partridge (617) 444-6108
Kelly Lewis (617) 444-7530


ALS-2200 (VX-135) Presentations

1. “ALS-2200, a Novel Once-Daily Nucleotide HCV Polymerase Inhibitor, Demonstrates Potent Antiviral Activity over 7 Days in Treatment-Naïve Genotype 1 (GT1) Patients.” November 11, 2012, 5:00 p.m. EST.
Oral Presentation #86

2. “Preclinical Characterization of ALS-2200, a Potent Nucleotide Polymerase Inhibitor for the Treatment of Chronic Hepatitis C.” November 13, 2012, 8:00 a.m. – 12:00 p.m. EST. Poster Presentation #1882

“Analysis of ALS-2200, a Novel Potent Nucleotide Analog, Combination Drug Interactions in the Hepatitis C Virus (HCV) Subgenomic Replicon System.” November 13, 2012, 8:00 a.m. – 12:00 p.m. EST. Poster Presentation #1887


INCIVEK (telaprevir) Presentations

1. “Telaprevir in Combination with Peginterferon Alfa-2a/Ribavirin in HCV/HIV Co-infected Patients: SVR24 Final Study Results.” November 11, 2012, 4:15 p.m. EST. Oral Presentation #54

2. “Evaluation of Liver and Plasma HCV RNA Kinetics and Telaprevir Levels in Genotype 1 HCV Patients Treated with Telaprevir using Serial Fine Needle Aspirates.” November 13, 2012, 9:00 a.m. EST. Oral Presentation #215

3. “The Safety of Telaprevir in the Absence of Interferon and/or Ribavirin: Analysis of On-Treatment Data from the ZENITH Trial.” November 11, 2012, 8:00 a.m. – 5:30 p.m. EST. Poster Presentation #786

4. “Factors Predictive of Anemia Development in Treatment-Experienced Patients Receiving Telaprevir (TVR) Plus Peginterferon/Ribavirin (PR) in the REALIZE Trial.” November 11, 2012, 8:00 a.m. – 5:30 p.m. EST. Poster Presentation #771

5. "Rate of Disappearance of Telaprevir Resistant Variants Using Clonal and Population Sequence Data from Phase 3 Studies.” November 11, 2012, 8:00 p.m. – 5:30 p.m. EST. Poster Presentation #756

6. “Deep Sequencing of the HCV NS3/4A Region Confirms Low Prevalence of the Telaprevir-Resistant Variants Both at Baseline and End of Study.” November 11, 2012, 8:00 p.m. – 5:30 p.m. EST. Poster Presentation #1091

VX-222 Presentations

1. “VX-222, Telaprevir and Ribavirin in Treatment-Naïve Patients with Genotype 1 Chronic Hepatitis C: Results of the ZENITH Study Interferon-Free Regimen.” November 13, 2012, 11:15 a.m. EST. Oral Presentation #231

“Effect of Hepatic Impairment on the Pharmacokinetics of VX-222: Results From a Multicenter Phase 1 Study.” November 13, 2012, 8:00 a.m. – 12:00 p.m. EST. Poster Presentation #1880